Last reviewed · How we verify
AdimFlu-S
AdimFlu-S, developed by National Cheng-Kung University Hospital, is a marketed influenza vaccine with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing availability to patients. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | AdimFlu-S |
|---|---|
| Sponsor | National Cheng-Kung University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
- Immunogenicity and Safety Evaluation of QIS in Healthy Subjects (PHASE3)
- Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects (PHASE4)
- The Safety and Immune Response to Influenza Vaccination in Pregnant Women (PHASE4)
- Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults (PHASE1, PHASE2)
- The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis (PHASE4)
- Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old (PHASE4)
- Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AdimFlu-S CI brief — competitive landscape report
- AdimFlu-S updates RSS · CI watch RSS
- National Cheng-Kung University Hospital portfolio CI